Medini E, Medini A, Gapany M, Levitt S H
Department of Radiation Oncology and Otolaryngology Veterans Administration Medical Center and University of Minnesota, Minneapolis 55417, USA.
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1211-3. doi: 10.1016/s0360-3016(96)00431-2.
The Purpose of this report is to present the local control rate and survival of patients treated by radiation therapy for T1N0M0 squamous cell carcinoma of the glottic larynx.
A total of 41 patients with squamous cell carcinoma of the glottis were treated at the Veterans Administration Medical Center Minneapolis, MN, between 1976 and 1990. Of the 41 patients, 40 are available for retrospective analysis with a minimum of a 2-year follow-up and a median follow-up of 5.8 years. Treatment was given to all the patients by a 4 MeV linear accelerator. The vast majority of the patients were treated with bilateral laryngeal opposed wedged 6 x 6 cm fields with a dose of 1.75 Gy per fraction to a total of 70 Gy in 40 fractions over 56 elapsed treatment days.
The data indicated local control and survival of 92.3 % at 2 years and 91.8 % at 3 years, post irradiation, with ultimate disease-free survival after surgical salvage of 97.4 % and 97.2 % at 2 years and 3 years, respectively. These local control and survival rates are comparable to those published in the literature when a higher fractional dose was given. No patients developed notable complications with our technique.
A dose of 1.75 Gy to 1.8 Gy per fraction to a total of 70 Gy in 56 elapsed treatment days is well tolerated and yields ultimate disease free-survival of 97.2% at 3 years. This time-dose fractionation could be used safely for treating patients who demonstrate low tolerance to irradiation with a risk of laryngitis, laryngeal edema, or difficulty of swallowing, with a higher fractional dose.
本报告旨在呈现接受放射治疗的声门型喉T1N0M0鳞状细胞癌患者的局部控制率和生存率。
1976年至1990年间,明尼苏达州明尼阿波利斯市退伍军人管理局医疗中心共治疗了41例声门型鳞状细胞癌患者。在这41例患者中,40例可进行回顾性分析,随访时间至少为2年,中位随访时间为5.8年。所有患者均采用4兆电子伏直线加速器进行治疗。绝大多数患者接受双侧喉对置楔形6×6厘米野照射,每次分割剂量为1.75戈瑞,在56个治疗日的40次分割中总剂量达70戈瑞。
数据显示,放疗后2年局部控制率和生存率分别为92.3%和91.8%,手术挽救后的最终无病生存率在2年和3年分别为97.4%和97.2%。当给予更高的分割剂量时,这些局部控制率和生存率与文献报道相当。采用我们的技术,无患者出现明显并发症。
在56个治疗日给予每次分割剂量1.75至1.8戈瑞,总剂量70戈瑞,耐受性良好,3年最终无病生存率为97.2%。这种时间 - 剂量分割方案可安全用于治疗对放疗耐受性低、有患喉炎、喉水肿或吞咽困难风险的患者,采用更高的分割剂量。